Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7105705 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Multiple Dose Placebo IV | PLACEBO_COMPARATOR | Healthy participants or participants with Alzheimer's disease will receive multiple doses of matching placebo IV QW, a total of 4 doses. |
| Multiple Dose RO7105705 IV | EXPERIMENTAL | Healthy participants or participants with Alzheimer's disease will receive multiple doses of RO7105705 IV QW, a total of 4 doses. |
| Single Dose RO7105705 SC | EXPERIMENTAL | Healthy participants will receive a single dose of RO7105705 SC on Day 1. |
| Single dose Placebo IV | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of placebo IV on Day 1. |
| Single dose RO7105705 IV | EXPERIMENTAL | Healthy participants will receive a single dose of RO7105705 IV on Day 1. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Participants will receive single or multiple doses of RO7105705 matching placebo IV. |
| RO7105705 | DRUG | Participants will receive single or multiple doses of RO7105705 IV or SC. |
Inclusion Criteria: All participants * Total body weight between 45 and 120 kilogram (kg), inclusive * Agreement not to donate blood or blood products for transfusion for the duration of the study and for 1 year after final dose of study drug * In good health, determined by no clinically significa...
Top 20 of 24 competitors
RO7105705 is an investigational small molecule being developed for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with mild-to-moderate Alzheimer's Disease, as well as in healthy participants.
RO7105705 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational small molecule for Alzheimer's Disease. Roche is responsible for the drug's development program.
RO7105705 is in Phase 1 clinical development. A Phase 1 study has been completed, which evaluated the drug in healthy participants and participants with mild-to-moderate Alzheimer's Disease. The drug is investigational and has not been approved for any use.
RO7105705 has one completed clinical trial registered as NCT02820896, titled "A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease." This Phase 1 study enrolled 74 participants in the United States and was a randomized, double-blind, placebo-controlled trial.
RO7105705 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Alzheimer's Disease. The completed Phase 1 trial was designed to assess safety and tolerability, and further studies would be needed before any regulatory approval could be considered.